CCL21 and lung adenocarcinoma: On the bases of improved outcomes in the animal model shown with GM.CD40L plus CCL21 and the limited options for previously treated patients with advanced or stage IV lung adenocarcinoma, we conducted a single-center phase I/randomized phase II trial to evaluate GM.CD40L vaccine plus/minus CCL21.